Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 15, Issue 9, 2013, Pages 776-785

  Owens, David R ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL FUNCTION; CHRONIC DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN INFUSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULIN TREATMENT; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; VASCULAR DISEASE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PSYCHOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; QUALITY OF LIFE;

EID: 84883328159     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0081     Document Type: Review

References (68)

1. Banting FG, Best CH: Pancreatic extracts. J Lab Clin Med 1922;7:464-472.
2. Banting FG, Best CH: The internal secretion of pancreas. J Lab Clin Med 1922;7:251-256.
3. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA, Macleod JJR: Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J 1922;12: 141-146.
4. Banting FG, Best CH, Collip JB, Macleod JJR, Noble EC: The effect of pancreatic extract (insulin) on normal rabbits. Am J Physiol 1922;62:162-176.
5. Banting FG, Campbell WR, Fletcher AA: Further experience with insulin in the treatment of diabetes mellitus. Br Med J 1923;i:8-12.
6. Marble A: Insulin in the treatment of diabetes. In: Marble A, White P, Bradley RF, Krall LP, eds. Joslin's Diabetes Mellitus, 11th ed. Philadelphia: Lea &Febiger, 1971:287-301.
7. Himsworth HP, Kerr RB: Insulin-sensitive and insulininsensitive types of diabetes mellitus. Clin Sci 1939;4:119.
8. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
9. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-Term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29.
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
11. Centers for Disease Control and Prevention: Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011;60:103-108.
12. Centers for Disease Control and Prevention: Vital signs: prevalence, treatment, and control of high levels of lowdensity lipoprotein cholesterol-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep 2011;60: 109-114.
13. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association, European Association for the Study of Diabetes: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
14. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association, European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
15. Dandona P, Chaudhuri A, Ghanim H, Mohanty P: Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007;99:15B-26B.
16. Dandona P, Chaudhuri A, Mohanty P, Ghanim H: Antiinflammatory effects of insulin. Curr Opin Clin Nutr Metab Care 2007;10:511-517.
17. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A: Insulin infusion in acute illness. J Clin Invest 2005;115:2069-2072.
18. Turner RC, McCarthy ST, Holman RR, Harris E: Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976;1:1252-1254.
19. Jetton TL, Liu YQ, Trotman WE, Nevin PW, Sun XJ, Leahy JL: Enhanced expression of insulin receptor substrate-2 and activation of protein kinase B/Akt in regenerating pancreatic duct epithelium of 60%-partial pancreatectomy rats. Diabetologia 2001;44:2056-2065.
20. Jetton TL, Lausier J, LaRock K, Trotman WE, Larmie B, Habibovic A, Peshavaria M, Leahy JL: Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes 2005;54:2294-2304.
21. Bouche C, Lopez X, Fleischman A, Cypess AM, O'Shea S, Stefanovski D, Bergman RN, Rogatsky E, Stein DT, Kahn CR, Kulkarni RN, Goldfine AB: Insulin enhances glucosestimulated insulin secretion in healthy humans. Proc Natl Acad Sci U S A 2010;107:4770-4775.
22. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34:222-234.
23. Engerman RL, Kern TS: Progression of incipent diabetic retinopathy during good glycemic control. Diabetes 1987;36: 808-812.
24. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
25. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865.
26. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
27. Ceriello A, Ihnat MA, Thorpe JE: Clinical review 2: the "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94:410-415.
28. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111.
29. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
30. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
31. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
32. GersteinHC,Yale JF,Harris SB, IssaM, Stewart JA,Dempsey E: A randomized trial of adding insulin glargine vs. avoidance of insulin in peoplewith Type 2 diabetes on either no oral glucoselowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-742.
33. Origin Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S: Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328.
34. Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hancu N, Hanefeld M, Krum H, Ryden L, Smith S, McQueen MJ, Dyal L, Yusuf S, Gerstein HC; GRACE and ORIGIN Investigators: Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE). Diabetes Care 2013 April 5 [Epub ahead of print]. doi: 10.2337/dc12-2129.
35. Retnakaran R, Drucker DJ: Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008;371:1725-1726.
36. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J: Induction of long-Term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-2602.
37. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-Term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356.
38. Park S, Choi SB: Induction of long-Term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19:124-130.
39. Ryan EA, Imes S, Wallace C: Short-Term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-1032.
40. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, TianH, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L,Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371: 1753-1760.
41. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD: Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-Term intensive insulin therapy. Diabetes Care 2008;31:1927-1932.
42. Chandra ST, Priya G, Khurana ML, Jyotsna VP, Sreenivas V, Dwivedi S, Ammini AC: Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Diabetes Technol Ther 2008;10:363-368.
43. Chon S, Oh S, Kim SW, Kim JW, Kim YS, Woo JT: The effect of early insulin therapy on pancreatic beta-cell function and long-Term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med 2010;25:273-281.
44. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, Bi Y, Weng J, Zhu D: Short-Term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and betacell function in subjects with long-Term remission. Diabetes Care 2011;34:1848-1853.
45. Harrison LB, Adams-Huet B, Raskin P, Lingvay I: Beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412.
46. Zeng L, Lu H, Deng H, Mu P, Li X, Wang M: Noninferiority effects on glycemic control and beta-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technol Ther 2012;14: 35-42.
47. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288-1293.
48. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361: 1736-1747.
49. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730.
50. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28: 1282-1288.
51. Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ: Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011;34:2048-2053.
52. Fonseca V, Gill J, Zhou R, Leahy J: An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011;13:814-822.
53. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist- Forbes E, Steen L, Orn T, Holberg MA, Kirksaether N, Grill V: Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008;10:421-429.
54. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26:2231-2237.
55. Pistrosch F, Kö hler C, Schaper F, Landgraf W, Forst T, Hanefeld M: Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol 2013; Feb 21 [Epub ahead of print]. doi: 10.1007/s00592-012-0451-9.
56. Hanefeld M, Fleischmann H, Landgraf W, Postrosch F: EARLY study: early basal insulin therapy under real-life conditions in type 2 diabetics. Diabetes Stoffwechsel Herz 2012;21:91-97.
57. Kunt T, Snoek FJ: Barriers to insulin initiation and intensification and how to overcome them. Int J Clin Pract Suppl 2009;(164):6-10.
58. Ziloz AV, Yang W, Gonzalez-Galvez G, Home P, Jianwen C, Hasan M: Prevalence of complications of diabetes in people with type 2 diabetes: data from Asia, Europe and Latin America from the A1chieve study [abstract 2485-PO]. Diabetes 2011;60:A656.
59. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams- Huet B, Raskin P: Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care 2009;32:1789-1795.
60. Asche CV, Bode B, Busk AK, Nair SR: The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:47-57.
61. Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC: Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007; 78:254-258.
62. Opsteen C, Qi Y, Zinman B, Retnakaran R: Effect of shortterm intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 2012;18:256-261.
63. Juneja R, Palmer JP: Type 1 1/2 diabetes: myth or reality? Autoimmunity 1999;29:65-83.
64. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG: A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006;29:970-975.
65. Poudel RR: Latent autoimmune diabetes of adults: from oral hypoglycemic agents to early insulin. Indian J Endocrinol Metab 2012;16(Suppl 1):S41-S46.
66. Thunander M, Thorgeirsson H, Torn C, Petersson C, Landin- Olsson M: Beta-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011;164:239-245.
67. Rosário PW, Reis JS, Fagundes TA, Calsolari MR, Amim R, Silva SC, Purisch S: Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization. Arq Bras Endocrinol Metabol 2007; 51:52-58.
68. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.